The Clinical Research On Eradicating Helicobacter Pylori,in Children By Furazolidone-contained Triple Therapy

Objective : Through prospective research,investigate the effect of furazolidone-contained triple therapy in eradicating H.pylori by comparing with the traditional standard triple therapies in children.Methods : Analyze the 66 child patients' cases being diagnosed with helicobacter pylori infection in Gastroenterology Clinic of Children's Hospital of Chongqing Medical University during April 2015 to July 2017,and make random continuous grouping to provide different therapeutic schedules: Group A:Furazolidone-contained triple therapy group:Furazolidone+Amoxicillin+Omeprazole with the treatment course of 10 days.Group B:Clarithromycin-contained therapy group:Clarithromycin+Amoxicillin+Omeprazole with the treatment course of 10 days.Group C: Clarithromycin-contained triple therapy group:Clarithromycin+Amoxicillin+Omeprazole with the treatment course of 14 days.Group D: Metronidazole-contained triple therapy group:Metronidazole+Amoxicillin+Omeprazole.Make assessment on the eradication rate,symptom relief and adverse drug reaction of anti-Hptreatment with different therapeutic schedules 2 weeks after the treatments begin and 4 weeks after the treatments finish for all child patients in the group.Results: 1.The eradication rates of Furazolidone-contained triple therapy(Group A),Clarithromycin-contained therapy with the treatment course of 10 days(Group B),Clarithromycin-contained triple therapy with the treatment course of 14 days(Group C)and Metronidazole-contained triple therapy(Group D)are 86.21%,69.23%,66.67% and 66.67%respectively,among which Furazolidone-contained triple therapy(Group A)has a higher eradication rate.2.Symptom relief: 2 weeks after the treatments begin,the symptom relief rates of each group are 89.66%,84.62%,77.78% and 93.33% respectively,among which Metronidazole-contained triple therapy(Group D)and Furazolidone-contained triple therapy(Group A)have the highest relief rates,though there is no statistical difference in relief rate among different groups(P > 0.05).3.Adverse reaction rate: during treatment,the adverse reaction rates of each group are13.79%,15.38%,0% and 6.67% respectively,but with no specific statistical significance in adverse reaction rates among different groups(P> 0.05).In comparison with the traditional triple therapies,adverse reaction is not common for Furazolidone-contained triple therapy.Conclusion:The eradication rate of Hp in the triple therapy group containing furazolidone(group A)was higher,but it was similar to thetraditional triple therapy in terms of symptom relief rate and incidence of adverse reactions.